RARE earnings: real EPS beat/miss history, analyst consensus Buy, P/E -4.52. Updated 2026-07-23.
Ultragenyx Pharmaceutical (RARE) Research Hub
Ultragenyx Pharmaceutical (RARE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 14.3 USD (-0.07%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.52, market cap 2.71B. This hub links to the full technical, earnings and options research available for RARE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 14.3 USD (-0.07%) |
| 52-week range | 13.81 USD – 36.57 USD |
| Trend regime | Range |
| 14-day RSI | 14.8 (Oversold) |
| Trailing P/E | -4.52 |
| Market cap | 2.71B |
| Dividend yield | 0.00% |
Available research for RARE
Covered Call on RARE: how it works, illustrative setup around the real 14.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RARE: how it works, illustrative setup around the real 14.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RARE: how it works, illustrative setup around the real 14.3 USD price, max profit/loss, breakeven and when to use it. Educational.
RARE technical analysis: range, last 14.3 USD, RSI 14.8, 52w range 13.81 USD–36.57 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is RARE in?
Ultragenyx Pharmaceutical (RARE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RARE in an uptrend or downtrend?
As of 2026-09-11, RARE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RARE's trailing P/E ratio?
RARE's trailing P/E is -4.52, with a market cap of 2.71B. See the earnings research page for full valuation detail.